SG
MRTX

Societe Generale’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Societe Generale’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$99K Buy
+18,049
New +$288K ﹤0.01% 2394

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Societe Generale's MRTX Position: Q2 2016 in Review

Societe Generale opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2016: 18,049 shares worth $99K. The stake represents ﹤0.01% of the portfolio and ranks #2394 among its holdings.

72 funds tracked by Wall St. Rank hold MRTX as of Q2 2016.

  • Societe Generale held 18,049 shares of Mirati Therapeutics, Inc. Common Stock worth $99K as of Q2 2016.
  • Mirati Therapeutics, Inc. Common Stock was a new Societe Generale position in Q2 2016.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2394 holding.
  • 72 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.